© PR Newswire
28.01.2026
GBT
LISTED
EURONEXT
Neue Indikation bei Kindern ab Geburt für Guerbets halbe Dosis GBCA, Elucirem™ (Gadopiclenol), von der Europäischen Kommission zugelassen
News Preview
VILLEPINTE, Frankreich, 28. Januar 2026 /PRNewswire/ -- Guerbet (FR0000032526 GBT), ein weltweit tätiger Spezialist für Kontrastmittel und Lösungen für die medizinische Bildgebung, freut sich, die Zulassung einer neuen Indikation für sein makrozyklisches Gadolinium-basiertes Kontrastmittel Elucirem™ (Gadopiclenol) bei Kindern ab der Geburt durch d...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.01.2026
TIVC
LISTED
NASDAQ
Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting
News Preview
January 26 Presentation highlighted Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposureBARDA has requested a follow-up meeting to continue the discussion on the potential utility of Entolimod as a drug for the Strategic National StockpileShowcased clinical results, regulatory...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.01.2026
TNON
LISTED
NASDAQ
Tenon(R) Medical Issues Shareholder Letter and Provides Preliminary Revenue for the Fourth Quarter and Full Year 2025
News Preview
Fourth Quarter 2025 Revenue of $1.45 to $1.48 Million, representing growth of ~90% year over year.Full Year 2025 Revenue of $3.91 to $3.94 Million, representing growth of ~20% year over year. LOS GATOS, CA / ACCESS Newswire / January 28, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining ca...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
28.01.2026
COPN
LISTED
SIX
Invitation to Cosmo's Full Year 2025 Financial Results Webcast on 9 March 2026
News Preview
Dublin, Ireland--(Newsfile Corp. - January 28, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Full-Year 2025 results on Monday, 9 March 2026 at 7:00 am CET. Live conference call and audio webcast presentation: Cosmo invites investors...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© ACCESS Newswire
28.01.2026
AIML
LISTED
CSE
AIML Appoints Dr. Paul Dorian as Medical Innovation Architect and Head of the Medical Advisory Board
News Preview
World Renowned Cardiologist and Research Leader to Guide Clinical Strategy, Product Innovation, and AI-Driven Cardiac Diagnostics TORONTO, ON / ACCESS Newswire / January 28, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce the appointment of Dr. Paul Dorian, MD, MSc...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
IDIA
LISTED
SIX
Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
128940
LISTED
KOE
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
News Preview
Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
ALT
LISTED
NASDAQ
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
News Preview
GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.01.2026
GENF
LISTED
LSE
Genflow Biosciences PLC Announces Administrative Approval of Grant & 2026 Priorities
News Preview
LONDON, UK / ACCESS Newswire / January 28, 2026 / THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
AGL
LISTED
NYSE
REMINDER: agilon health, inc. Investors With Significant Losses Must Act By March 2, 2026
News Preview
Kirby McInerney LLP reminds agilon health, inc. (“agilon” or the “Company”) (NYSE:AGL) investors of the March 2, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may infl...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
VEEV
LISTED
NYSE
Branchenstudie zeigt: Schaffung einer Grundlage für KI hat für Konsumgüterunternehmen höchste Priorität
News Preview
82 % der Unternehmen stellen auf einheitliche Plattformen für standardisierte Daten und Prozesse um und bereiten sich auf KI vorBARCELONA, Spanien, 27. Januar 2026 /PRNewswire/ -- Ein neuer Branchenbericht zeigt, dass der Aufbau einer KI-fähigen Infrastruktur für Konsumgüterunternehmen (CPG) oberste Priorität hat. Der Bericht State of AI in Consum...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
BDX
LISTED
NYSE
BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26
News Preview
FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on March 31, 2026, to holders of record on March 10, 2026. The indicated annual dividend r...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
27.01.2026
BBIO
LISTED
NASDAQ
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the first paragraph were incorrect. The corrected release follows:...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
ELMD
LISTED
XASE
Electromed, Inc. to Report Q2 Fiscal 2026 Financial Results on February 10, 2026
News Preview
Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 second quarter ended December 31, 2025, on Tuesday, February 10, 2026 after the close of the stock market. Company management will h...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
EXEL
LISTED
NASDAQ
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
News Preview
Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
CDNA
LISTED
NASDAQ
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
News Preview
CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ —, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the BTIG 13th Annual MedTech, Digital Health...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
GILD
LISTED
NASDAQ
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2025 financial resul...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
INNO
LISTED
CSE
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
News Preview
HERZLIYA, Israel and CALGARY, AB, Jan. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, today announced that, further to its press release dated January 2, 2026, it now an...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
INNO
LISTED
CSE
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
News Preview
HERZLIYA, Israel and CALGARY, AB, Jan. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, today announced that, further to its press release dated January 2, 2026, it now an...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
INNO
LISTED
CSE
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
News Preview
HERZLIYA, Israel and CALGARY, AB, Jan. 27, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, today announced that, further to its press release dated January 2, 2026, it now anticipat...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
JNJ
LISTED
NYSE
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
News Preview
Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twelfth indication for DARZALEX FASPRO® and fifth in the newly diagnosed setting, underscoring its role as foundational therapy for both newly diagnosed and rel...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
AIMI
LISTED
OTC
AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering
News Preview
OCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, announced today changes to the previously announced key da...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
MRK
LISTED
NYSE
Merck Announces Second-Quarter 2026 Dividend
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock for the second quarter of 2026. Payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026.
About...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
ADPT
LISTED
NASDAQ
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
News Preview
SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
PACB
LISTED
NASDAQ
PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
News Preview
MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, at 5:00 pm Eastern Time....
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
STOK
LISTED
NASDAQ
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
News Preview
New Headquarters Will Support Company's Work to Deliver zorevunersen, a Potential Disease-Modifying Medicine, to Patients with Dravet Syndrome and Expansion of Research EffortsLease is One of the Largest in Greater Boston Life Sciences Over the Past YearWALTHAM, Mass., Jan. 27, 2026 /PRNewswire/ -- Anchor Line Partners, LLC and Northwood Investors...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
GBT
LISTED
EURONEXT
New indication in children from birth for Guerbet's half-dose GBCA, Elucirem™ (Gadopiclenol) approved by European Commission
News Preview
VILLEPINTE, France, Jan. 27, 2026 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a global specialist in contrast media and solutions for medical imaging, is delighted to announce the approval by European Commission of a new indication in children from birth for its macrocyclic high-relaxivity gadolinium-based contrast agent, Elucirem™ (gadopiclenol)...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
1521
LISTED
HKSE
Frontage Europe Has Relocated Its Bioanalytical Laboratory and Further Expands Its Capabilities
News Preview
EXTON, Pa., Jan. 27, 2026 /PRNewswire/ -- We are pleased to communicate that Frontage Europe, a fully owned subsidiary of Frontage Laboratories Inc., has relocated its bioanalytical laboratory to consolidate all services in a 2,500 square meters facility close to Milan, Italy. This strategic decision represents a step forward to increase efficienc...
Themefolio
Profiler
Peergroup
© ActuNews
27.01.2026
ALTHX
LISTED
EURONEXT
THERANEXUS : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONFIÉ À PORTZAMPARC
News Preview
Lyon, France – 27 janvier 2026, 18h CET – THX Pharma (Theranexus), société biopharmaceutique innovante dans le traitement des maladies neurologiques rares, publie aujourd'hui le bilan semestriel de son contrat de liquidité confié à Portzamparc.
Au titre du contrat de liquidité confié...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
BAYN
LISTED
XETR
Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada
News Preview
Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada’s leadership in canola innovation by establishing a cutting-edge canola innovation centre. Located in Winnipeg, Manitoba, the facility will house seed development work for canola, camelina and winter canola, focusing on trait integration, yield tri...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
45520
LISTED
XJPX
JCR Pharmaceuticals to Present at the 22nd Annual WORLDSymposium™ 2026
News Preview
JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced today that it will present data at the 22nd Annual WORLDSymposium™ 2026, held February 2-6, 2026, in San Diego, Calif. The poster presentations will demonstrate the potential benef...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
MRK
LISTED
NYSE
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
News Preview
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 27, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global oncology therapy market is charging toward a massive $668 billion valuation by 2034, as a ruthless capital rotation finally rewards execution-ready platforms over the "hopes and dreams" of speculative discovery as...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
MRK
LISTED
NYSE
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
News Preview
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary – The global oncology therapy market is charging toward a massive $668 billion valuation by 2034, as a ruthless capital rotation finally rewards execution-ready platforms over the "hopes and dreams" of speculative discovery assets[1]...
Themefolio
Profiler
Peergroup
© EQS Newswire
27.01.2026
VME
LISTED
XETR
MHH to Present Scientific Findings on Cold Plasma Therapy for Pulmonary Application at Press Conference in February 2026
News Preview
PRESS RELEASE
MHH to Present Scientific Findings on Cold Plasma Therapy for Pulmonary Application at Press Conference in February 2026
Rellingen, 27 January 2026 – On 12 February 2026, Hannover Medical School (MHH) – represented by Prof. Dr. Hortense Slevogt – plans to hold a press conference together with the team from the Helmholtz Centre for I......
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
LNAI
LISTED
NASDAQ
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons
News Preview
Transformer-based biosecurity layer embeds directly into foundation models, using Lunai's proprietary toxicology and in-vivo datasets to detect and prevent creation of previously unknown threat agents in real time.SACRAMENTO, Calif., Jan. 27, 2026 /PRNewswire/ -- As global attention intensifies around the dual-use risks of advanced artificial inte...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
NNOX
LISTED
NASDAQ
AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B Market
News Preview
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, Jan. 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – The global medical imaging market hit a massive $45.5 billion in 2026[1], marking a total structural shift toward AI-native precision as advanced cancer therapies demand more intense heart monitoring than ever before[2]. Hospita...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
NNOX
LISTED
NASDAQ
AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B Market
News Preview
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, Jan. 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The global medical imaging market hit a massive $45.5 billion in 2026[1], marking a total structural shift toward AI-native precision as advanced cancer therapies demand more intense heart monitoring than ever before[2]....
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2026
AYTU
LISTED
NASDAQ
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
News Preview
DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its seco...
Themefolio
Profiler
Peergroup
© Newsfile
27.01.2026
NURL
LISTED
CSE
Neural's Portfolio Company Hanf.com Announces Sales Start of Ritual Herbs Nicotine and Tobacco Free Products
News Preview
Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("C...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
BDX
LISTED
NYSE
BD to Announce Financial Results for its First Quarter of Fiscal 2026
News Preview
FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Monday, February 9, 2026 to discuss the Company's financial results for its first quarter of fiscal year 2026, which ended on ...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
BDX
LISTED
NYSE
Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business
News Preview
Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transactionMILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareh...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
BDX
LISTED
NYSE
Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business
News Preview
Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transactionMILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareh...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
BDX
LISTED
NYSE
BD Announces Record Date for the Spin-Off of its Biosciences & Diagnostic Solutions Business
News Preview
Distribution date and closing date for spin-off and merger with Waters Corporation set for February 9, 2026FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) ("BD" or the "Company") today announced that the Company's Board of Directors has set the close of business on February 5, 2026, as the record...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
VREX
LISTED
NASDAQ
Varex Schedules First Quarter Fiscal Year 2026 Earnings Release and Conference Call
News Preview
Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the first quarter of fiscal year 2026, following the close of regular trading on Tuesday, February 10, 2026. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day.
This call will be webcast live...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
3696
LISTED
HKSE
Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies
News Preview
CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innova...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
6446
LISTED
TAI
PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET)
News Preview
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the U.S. NCCN Clinical Practice Guidelines in Oncology have been updated t...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
ANEB
LISTED
NASDAQ
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer
News Preview
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced the preliminary results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
ANIX
LISTED
NASDAQ
Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology
News Preview
Notice of Allowance marks first Mexican patent to be issued on Anixa Breast Cancer VaccineExpands global intellectual property coverage in markets with greater late-stage breast cancer diagnoses and higher triple-negative breast cancer incidence ratesSAN JOSE, Calif., Jan. 27, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
DXCM
LISTED
NASDAQ
Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.
News Preview
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 12, 2026. Management will hold a conference call to review the company's fourth quarter and fiscal year 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The con...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
TEM
LISTED
NASDAQ
Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune Profile Score (IPS), more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) than conventional biomarkers, includ...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
INMB
LISTED
NASDAQ
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
News Preview
Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO:...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
SVRA
LISTED
NASDAQ
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with Hercules Capital, Inc. (NYSE:HTGC), strengthening its balance sheet and liquidity.
Under the terms of the amended loan agreement, up to an additional $75...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
DCTH
LISTED
NASDAQ
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference at the Cliff Lodge in Snowbird, Utah.
About Delcath System...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
KZIA
LISTED
NASDAQ
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
News Preview
SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC).
To date, three patients with metastatic TNBC treat...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
VNRX
LISTED
XASE
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
News Preview
Nu.Q® Biomarker Paper Available on MedRXIV HENDERSON, Nev., Jan. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the release of a new clinical study demonstrating the use of its Nu.Q® NETs assay in patient management for a chronic disease, Hidradenitis Suppurativa (HS)...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
BNBX
LISTED
NASDAQ
BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th
News Preview
BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will present live at the Digital Asset Virtual Investor Conference hosted by Virtual InvestorConferences.com, on January 27th, 2026 at 1:00PM EST.
DATE: January 27th, 2026
TIME: 1:00P...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
ATRC
LISTED
NASDAQ
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026.
AtriCure will host an audio...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
JNJ
LISTED
NYSE
Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile
News Preview
Johnson & Johnson, with support from the Johnson & Johnson (J&J) Foundation, announced that it has donated $100 million of MedTech products since 2020 to help more people around the world access the specialized care they need to live, see and smile. The Company has also planned to contribute an additional $20 million toward programs an...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
AHCO
LISTED
NASDAQ
AdaptHealth Corp. Announces Upgraded Moody’s Ratings
News Preview
AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that Moody’s Ratings (Moody’s) has recently upgraded the ratings of AdaptHealth, LLC, including the Corporate Fami...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
